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LETTERS TO THE EDITOR
Prognostic Value of Heart
Rate Variability in
Idiopathic Dilated Cardiomyopathy
We read with interest the report by Fauchier et al. (1), regarding
the prognostic value of heart rate variability for sudden death and
major arrhythmic events in patients with idiopathic dilated cardio-
myopathy. Their results showed that a decrease in heart rate
variability was an independent predictor of arrhythmic events and
sudden death in idiopathic dilated cardiomyopathy. They sug-
gested that it was not previously demonstrated. However, Szabo et
al. (2) studied the prognostic value of heart rate variability in
chronic congestive heart failure secondary to idiopathic or ischemic
dilated cardiomyopathy. Their patient group consisted of 178
patients (40 with idiopathic dilated cardiomyopathy, mean ejection
fraction 28%). Four (10%) of the 40 patients had a sudden cardiac
death during a follow-up of 23 months. Prognostic factors for
sudden cardiac death were left ventricular ejection fraction ,27%
and standard deviation of the averages of NN intervals ,108 ms.
The authors reported that impairment of heart rate variability
variables was correlated with an increased risk of cardiac death and
that heart rate variability appeared to have independent prognostic
value in congestive heart failure. In the study of Faucher et al., 116
patients with idiopathic dilated cardiomyopathy (ejection fraction
34 6 12%, mean follow-up 53 6 39 months) were investigated.
Seven patients (6%) had a sudden cardiac death.
In our opinion, despite the small group and the short follow-up,
the results of the study of Szabo et al. should have been taken into
consideration in Fauchier et al.’s study.
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REPLY
In response to the letter by Eryonucu et al., we considered with
great interest the report by Szabo et al. (1). We are in absolute
disagreement with Eryonucu about the prognostic value demon-
strated in this study for the specific end point of sudden death (1).
In this brief report, it was clearly stated that a low left ventricular
ejection fraction was the only predictor of sudden death in this
series of patients with congestive heart failure due to ischemic or
idiopathic dilated cardiomyopathy, with a follow-up time half of
that in our study (2). A decrease in heart rate variability was not a
predictor of sudden death nor was it included in the univariate or
multivariate analysis (Table 2). Moreover, we took into account
the occurrence of major arrhythmic events (sustained ventricular
tachycardia or ventricular fibrillation), whereas these events were
not considered by Szabo et al. In view of the several mechanisms
of sudden death in congestive heart failure, we consider that the
mixed end point of “sudden death or major arrhythmic events” is
probably the most specific one if there is a mechanism of
ventricular tachyarrhythmia that may be adequately treated by an
implantable cardioverter-defibrillator. Clearly, the results of our
study may be more helpful for the rationale of future prophylactic
studies about implantable cardioverter-defibrillator placement in
the particular situation of idiopathic dilated cardiomyopathy.
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Coronary Flow Reserve Assessment
From Average Peak Velocity Profiles
Alone Must Be Judged With Caution
We enjoyed the study by Caiati et al. (1) on contrast-enhanced
transthoracic second harmonic Doppler echocardiography with
adenosine for noninvasive coronary flow reserve (CFR) assessment,
which confirmed the very similar data from their recent study using
dipyridamole (2). Although the results are interesting, we would
like to comment on methodologic issues.
First, it should be emphasized that the assessment of CFR by
using the ratio of hyperemic to basal peak velocity is not entirely
correct, as it relies on the assumption of an invariate shape of the
velocity profile. In fact, the error introduced by changes of the flow
velocity profile has been shown to be as high as 11% (3).
Second, the spatial resolution in this study does not allow vessel
visualization. No accurate CFR assessment can be done by velocity
information alone, without knowing the exact vessel size, unless
this variable cancels out because vessel size remains constant.
However, it is a well-documented fact (see, for example, reference
6 of the study [4]) that adenosine leads to significant coronary
dilation, severely affecting the relation between coronary flow
velocity and volumetric flow, thus introducing an error of up to
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40%. This problem is usually addressed by using nitroglycerin
before the baseline measurement to achieve maximal dilation
throughout the study. However, this was not done in the study by
Caiati et al. Thus, the authors’ statement that “vessel size does not
change with respect to the baseline so vessel size cancels out” is
simply untrue, and this is emphasized by a recent study reporting
that such a lack of epicardial coronary dilation response to
adenosine is diagnostic for microvascular disease (5). These two
facts may add up to a substantial underestimation of CFR and, at
least in part, explain why the normal value in this study (2.88) is
considerably lower than that obtained after predilation with
nitroglycerin (3.4) (4) or with other established methods such as
positron emission tomography (3.5–4.0) (6).
Third, the authors use an infusion rate of 0.5 to 2 ml/min of
echo contrast agent, referring to a previous report (2) quoting two
studies (7,8) in which the infusion rate was 2 ml/s. We wonder
whether there might have been a typing error or additional data
justifying a slowing of the infusion rate by a factor 60.
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REPLY
Drs. Kaufmann and Jenni pointed out that a reason for the error in
assessing coronary flow reserve with this novel Doppler method
with adenosine (1) could be both the flow-mediated dilation of the
epicardial vessel during hyperemia and the hyperemia-induced
variation of blood flow velocity profile. In addition, they observed
a large discrepancy between the contrast infusion modalities used
in this recent study and those used in our previous studies.
Regarding the first point, the published data are controversial
and scanty. In fact, an animal study using intravascular echocar-
diography has shown no variation of epicardial coronary vessel size
during intracoronary adenosine (2). In another human study
conducted in patients with and without left main coronary artery
disease, intravenous adenosine did not increase the angiographic
lumen diameter in the mid and distal segments (control 3.39 6
0.85 vs. 3.35 6 0.98 mm after adenosine; percent change 21 6
12%) as compared with the proximal epicardial vessel diameter
(control 3.72 6 0.99 vs. 3.72 6 0.86 mm after adenosine; percent
change 1 6 6%) (3).
Flow-mediated dilation, if any, should not always take place.
Flow-mediated vasodilation is, in fact, impaired both in patients
without increment of flow (in which, of course, no shear stress can
be exerted on the coronary endothelium) and in patients with no
flow-limiting atherosclerosis (4). Therefore, in our study, flow-
mediated vasodilation, if any, should have affected the assessment
of coronary flow reserve only in patients with preserved capacity to
increase flow (no flow-limiting stenosis) and, at the same time,
without overt atherosclerosis of the left anterior descending coro-
nary artery. This refers to only a small percentage of group 1 in our
series. In addition, the data cited by Kaufmann et al. refer mostly
to studies in which an intracoronary bolus of adenosine or papaverine
was administered. In contrast, in our study, intravenous adenosine was
used. It can be hypothesized that a vasodilator agent administered
through the intravenous route can have less effect on the conductance
vessel (only an indirect effect, if any, through increment of flow), as
compared with the intracoronary route (direct effect of bolus and
indirect flow-mediated action) (5). A major impact of flow-mediated
dilation could be hypothesized in studies in which endothelial dys-
function in the absence of coronary artery disease has to be evaluated.
Further studies are needed to shed more light on this issue.
Regarding their second point, the hyperemia-induced blood
flow velocity profile variation is a minor limitation (relatively small
source of error, 12%) of any Doppler method that affects not only
our new noninvasive method but also the intracoronary Doppler
flow wire method.
Regarding their third point, a careful reading of the Methods
sections of this recent study and previous reports would have avoided
any confusion. In fact, there is no contradiction with the previous
experience, because, as correctly specified, only the concentration of
the agent (300 mg/ml) was the same as that in the previous
experience. The modality of administration, however, has changed
radically. Now we use, as reported (1), an infusion through a pump
with an infusion rate of 1 ml/min, where in the past, we manually
injected contrast as a bolus (at ;2 ml/s). The advantage of this new
modality has been addressed in a recent paper of ours (6).
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